SI1954308T1 - Stabilizatorji za liofilizirana cepiva - Google Patents

Stabilizatorji za liofilizirana cepiva

Info

Publication number
SI1954308T1
SI1954308T1 SI200631180T SI200631180T SI1954308T1 SI 1954308 T1 SI1954308 T1 SI 1954308T1 SI 200631180 T SI200631180 T SI 200631180T SI 200631180 T SI200631180 T SI 200631180T SI 1954308 T1 SI1954308 T1 SI 1954308T1
Authority
SI
Slovenia
Prior art keywords
stabilizers
freeze
live attenuated
present
dried vaccines
Prior art date
Application number
SI200631180T
Other languages
English (en)
Inventor
Delphine Magali Belin-Poput
Noel Yves Henri Jean Genin
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of SI1954308T1 publication Critical patent/SI1954308T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SI200631180T 2005-09-16 2006-09-15 Stabilizatorji za liofilizirana cepiva SI1954308T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71764005P 2005-09-16 2005-09-16
EP06814694A EP1954308B1 (en) 2005-09-16 2006-09-15 Stabilizers for freeze-dried vaccines
PCT/US2006/035944 WO2007035455A2 (en) 2005-09-16 2006-09-15 Stabilizers for freeze-dried vaccines

Publications (1)

Publication Number Publication Date
SI1954308T1 true SI1954308T1 (sl) 2011-12-30

Family

ID=37808009

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631180T SI1954308T1 (sl) 2005-09-16 2006-09-15 Stabilizatorji za liofilizirana cepiva

Country Status (15)

Country Link
US (1) US8784843B2 (sl)
EP (1) EP1954308B1 (sl)
JP (1) JP5275803B2 (sl)
CN (1) CN101312742B (sl)
AT (1) ATE523207T1 (sl)
CY (1) CY1112490T1 (sl)
DK (1) DK1954308T3 (sl)
ES (1) ES2373238T3 (sl)
HR (1) HRP20110803T1 (sl)
ME (1) ME01965B (sl)
PL (1) PL1954308T3 (sl)
PT (1) PT1954308E (sl)
RS (1) RS51996B (sl)
SI (1) SI1954308T1 (sl)
WO (1) WO2007035455A2 (sl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
DK1973406T3 (da) 2005-12-28 2014-06-23 Advanced Bionutrition Corp Fremføringsmiddel til probiotiske bakerier omfattende en tør blanding af polysaccharider, saccharider, polyoler i glasform
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN101489587B (zh) * 2006-05-12 2015-05-27 伯哈拉特生物技术国际有限公司 一种可用作疫苗的组合物
EP2117354B1 (en) 2006-12-18 2018-08-08 Advanced BioNutrition Corp. A dry food product containing live probiotic
CN101903041A (zh) * 2007-12-21 2010-12-01 辉瑞大药厂 经热处理的菌苗,及由这些经热处理的菌苗制备的乳剂疫苗
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
CN102459578A (zh) * 2009-01-30 2012-05-16 俄克拉荷马州大学评议会 基于在北美狗中循环的犬瘟热病毒的免疫原性组合物、疫苗和诊断方法
EP2410996B1 (en) 2009-03-27 2017-08-02 Advanced Bionutrition Corp. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
SG176253A1 (en) * 2009-05-26 2011-12-29 Advanced Bionutrition Corp Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
WO2011094469A2 (en) 2010-01-28 2011-08-04 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
WO2011121306A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
GB2490644A (en) 2010-03-31 2012-11-07 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
ES2874817T3 (es) 2010-04-15 2021-11-05 Shin Nippon Biomedical Laboratories Ltd Procedimiento para generar una formulación de vacuna en polvo seco para suministro intranasal
LT2603100T (lt) 2010-08-13 2018-07-25 Advanced Bionutrition Corp. Stabilizuojanti kompozicija, skirta biologinių medžiagų sausam saugojimui
EP2627774B1 (en) * 2010-10-15 2018-11-21 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) influenza vaccine
DK2646052T3 (en) 2010-12-02 2017-07-17 Oncolytics Biotech Inc LYOPHILIZED VIRAL FORMULATIONS
TW201233802A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Liquid viral formulations
CN102228687B (zh) * 2011-06-24 2012-10-10 浙江普康生物技术股份有限公司 不含明胶、人血白蛋白保护剂的冷冻干燥甲型肝炎减毒活疫苗及制备方法
SI2734230T1 (sl) * 2011-07-20 2019-04-30 Merial Limited Rekombinantno cepivo proti virusu mačje levkemije, ki vsebuje optimiziran gen ovojnice virusa mačje levkemije
ES2626297T3 (es) * 2011-08-12 2017-07-24 Merial, Inc. Preservación asistida por vacío de productos biológicos, en particular de vacunas
GB201117233D0 (en) * 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
JP2015500864A (ja) * 2011-12-23 2015-01-08 ノバルティス アーゲー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対して免疫するための安定な組成物
CN102488894B (zh) * 2011-12-31 2014-08-20 齐鲁动物保健品有限公司 一种狐狸脑炎活疫苗及其制备方法
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
CN102854313A (zh) * 2012-09-29 2013-01-02 黑龙江省农业科学院植物脱毒苗木研究所 马铃薯y病毒阳性对照品的制备方法
CN102920669A (zh) * 2012-11-09 2013-02-13 湖北凤凰白云山药业有限公司 一种甘露醇冻干粉的制备方法
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
CA2923010C (en) 2013-09-03 2022-08-30 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
AR097762A1 (es) * 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US10429129B2 (en) 2013-10-16 2019-10-01 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
EP3057611A4 (en) 2013-10-16 2017-04-12 Merck Sharp & Dohme Corp. Thermostable respiratory synctial virus (rsv) vaccine compositions
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
FR3034418B1 (fr) * 2015-04-03 2018-09-28 Roquette Freres Utilisation de combinaisons particulieres de carbohydrates pour stabiliser des proteines, et compositions proteiques contenant de telles combinaisons
US10953050B2 (en) 2015-07-29 2021-03-23 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
JP6855469B2 (ja) * 2015-10-16 2021-04-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 消化器標的療法のための処方物を調製するための工程
EP3436054B2 (en) 2016-09-13 2022-07-27 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
NL2018155B1 (en) 2017-01-11 2018-07-25 Intervet Int Bv Oral vaccine against ruminant respiratory disease
GB201701239D0 (en) 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
WO2019236435A1 (en) * 2018-06-07 2019-12-12 Merck Sharp & Dohme Corp. Lyosphere critical reagent kit
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
CN111707512A (zh) * 2020-06-15 2020-09-25 深圳市瑞赛生物技术有限公司 即用型维生素标准品及其制备方法、使用方法和贮存稳定剂
CN112057603B (zh) * 2020-07-25 2023-07-14 艾美卫信生物药业（浙江）有限公司 一种白喉毒素无毒突变体crm197蛋白的冻干方法
CN115624630A (zh) * 2022-12-19 2023-01-20 北京荷牧生物科技有限公司 冻干保护组合物及其应用和基于该组合物的核酸脂质纳米颗粒冻存方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1108956A (en) * 1964-05-26 1968-04-10 Ciba Ltd Process for the manufacture of bcg vaccines
US3783098A (en) * 1971-08-10 1974-01-01 Cornell Res Foundation Inc Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
JPS4840990A (sl) * 1971-10-04 1973-06-15
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
JPS6281327A (ja) * 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH07121871B2 (ja) * 1986-10-09 1995-12-25 国立予防衛生研究所長 インフルエンザワクチン凍結乾燥製剤
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
US5147756A (en) * 1991-04-11 1992-09-15 E. I. Du Pont De Nemours And Company Stabilized, aqueous hydrazide solutions for photographic elements
AU2088992A (en) * 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
AU7971194A (en) * 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
JPH08176011A (ja) * 1994-12-21 1996-07-09 Dot:Kk 無菌性骨壊死症候群治療剤
WO1996029096A1 (fr) * 1995-03-17 1996-09-26 Hisamitsu Pharmaceutical Co., Inc. Preparation de transfert genique
JP3193057B2 (ja) * 1995-03-17 2001-07-30 久光製薬株式会社 遺伝子導入製剤
JPH08333277A (ja) * 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
FR2750865B1 (fr) * 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
KR100768114B1 (ko) * 1999-06-10 2007-10-17 메리알 애완 동물 및 스포츠용 동물을 위한 ｄｎａ 백신
JP2002326924A (ja) * 2001-05-07 2002-11-15 Hayashibara Biochem Lab Inc 洗顔料
AU2004299057B2 (en) * 2003-12-17 2010-06-24 Wyeth Llc Methods for porducing storage stable viruses and immunogenic compositions thereof
WO2005066333A1 (en) * 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions

Also Published As

Publication number Publication date
CY1112490T1 (el) 2015-12-09
PT1954308E (pt) 2011-11-03
ES2373238T3 (es) 2012-02-01
ME01965B (me) 2012-04-30
US20100260796A1 (en) 2010-10-14
CN101312742A (zh) 2008-11-26
PL1954308T3 (pl) 2012-01-31
JP2009508866A (ja) 2009-03-05
RS51996B (en) 2012-04-30
DK1954308T3 (da) 2011-10-24
EP1954308B1 (en) 2011-09-07
CN101312742B (zh) 2012-07-25
HRP20110803T1 (hr) 2011-11-30
ATE523207T1 (de) 2011-09-15
WO2007035455A2 (en) 2007-03-29
EP1954308A2 (en) 2008-08-13
WO2007035455A3 (en) 2007-07-26
US8784843B2 (en) 2014-07-22
JP5275803B2 (ja) 2013-08-28

Similar Documents

Publication Publication Date Title
SI1954308T1 (sl) Stabilizatorji za liofilizirana cepiva
MY150613A (en) Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
WO2009156405A8 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
PH12015500773A1 (en) Methods and compositions for live attenuated viruses
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MY171210A (en) Stabilized soluble pre-fusion rsv f polypeptides
MX2010003242A (es) Volatiles vegetales.
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
MX2009006178A (es) Vacuna contra salmonela.
TN2009000398A1 (en) 5,6-dihydro-1h-pyridin-2-one compounds
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
MX2020001885A (es) Formulaciones de daptomicina.
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
GB201017519D0 (en) Vaccines
MX2011008179A (es) Peptidos para vacuna.
WO2012054907A3 (en) Novel hemagglutinin 5 (h5) proteins for the treatment and prevention of influenza infections
WO2011032108A3 (en) Formulation for room temperature stabilization of a live attenuated bacterial vaccine
PH12018500675A1 (en) Stable live attenuated recombinant dengue vaccine
GB2568440A (en) Modified factor H binding protein
WO2014167582A3 (en) Vaccine composition for prophylaxis in ruminants
WO2007028985A3 (en) Adjuvanted vaccine
MX2018011016A (es) Formulaciones estables para liofilizar particulas terapeuticas.